Back to Search Start Over

F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system

Authors :
Anna Kruczynski
Christian Bailly
Thierry Imbert
Stéphane Vispé
Viviane Brel
Jean-Philippe Annereau
Jean-Marc Barret
Amélie Lansiaux
Nicolas Guilbaud
Jean-Guy Delcros
Yves Guminski
Centre de Recherche en Oncologie Expérimentale
PIERRE FABRE
Division de Chimie Médicinale III
Institut de Génétique et Développement de Rennes (IGDR)
Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1)
Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille
Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc)
Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille
De Villemeur, Hervé
Source :
Cancer Research, Cancer Research, American Association for Cancer Research, 2008, 68 (23), pp.9845-53. ⟨10.1158/0008-5472.CAN-08-2748⟩, Cancer Research, 2008, 68 (23), pp.9845-53. ⟨10.1158/0008-5472.CAN-08-2748⟩
Publication Year :
2008
Publisher :
HAL CCSD, 2008.

Abstract

The polyamine transport system (PTS) is an energy-dependent machinery frequently overactivated in cancer cells with a high demand for polyamines. We have exploited the PTS to selectively deliver a polyamine-containing drug to cancer cells. F14512 combines an epipodophyllotoxin core-targeting topoisomerase II with a spermine moiety introduced as a cell delivery vector. The polyamine tail supports three complementary functions: (a) facilitate formulation of a water-soluble compound, (b) increase DNA binding to reinforce topoisomerase II inhibition, and (c) facilitate selective uptake by tumor cells via the PTS. F14512 is 73-fold more cytotoxic to Chinese hamster ovary cells compared with CHO-MG cells with a reduced PTS activity. A decreased sensitivity of L1210 leukemia cells to F14512 was observed in the presence of putrescine, spermidine, and spermine. In parallel, the spermine moiety considerably enhances the drug-DNA interaction, leading to a reinforced inhibition of topoisomerase II. The spermine tail of F14512 serves as a cell delivery vehicle as well as a DNA anchor, and this property translates at the cellular level into a distinct pharmacologic profile. Twenty-nine human solid or hematologic cell lines were used to characterize the high cytotoxic potential of F14512 (median IC50 of 0.18 μmol/L). Finally, the potent antitumor activity of F14512 in vivo was evidenced with a MX1 human breast tumor xenograft model, with partial and complete tumor regressions. This work supports the clinical development of F14512 as a novel targeted cytotoxic drug and sheds light on the concept of selective delivery of drugs to tumor cells expressing the PTS. [Cancer Res 2008;68(23):9845–53]

Details

Language :
English
ISSN :
00085472 and 15387445
Database :
OpenAIRE
Journal :
Cancer Research, Cancer Research, American Association for Cancer Research, 2008, 68 (23), pp.9845-53. ⟨10.1158/0008-5472.CAN-08-2748⟩, Cancer Research, 2008, 68 (23), pp.9845-53. ⟨10.1158/0008-5472.CAN-08-2748⟩
Accession number :
edsair.doi.dedup.....d2bf593d5751d6a6d5aadb66777615b8
Full Text :
https://doi.org/10.1158/0008-5472.CAN-08-2748⟩